Three Cases of Cytopenia during Azathioprine Treatment for Bullous Disease / 대한피부과학회지
Korean Journal of Dermatology
;
: 265-268, 2018.
Artículo
en Coreano
| WPRIM
| ID: wpr-714498
ABSTRACT
Azathioprine is an immunosuppressive drug that has been widely used in dermatology for the treatment of immunobullous diseases. Myelosuppression is the most important side effect and requires close observation of the complete blood cell count. The clinical findings of myelosuppression include general weakness, poor oral intake, nausea, dyspnea, and pallor. It can occur within several weeks to years after initial azathioprine treatment; thus, a weekly full blood count for the first 4 weeks, followed by reduced frequency of monitoring to a minimum of once every 3 months is recommended. If the myelosuppression is not treated properly, it can lead to fever, secondary infection, sepsis, and even death. Herein, we present three educational cases for dermatologists to order to underline the risk of myelosuppression during azathioprine treatment.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Palidez
/
Azatioprina
/
Recuento de Células Sanguíneas
/
Sepsis
/
Dermatología
/
Disnea
/
Fiebre
/
Coinfección
/
Náusea
Idioma:
Coreano
Revista:
Korean Journal of Dermatology
Año:
2018
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS